First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
value - The stock trades at reasonable valuation multiples (3.5x P/S, 10.9x EV/EBITDA) relative to biotech peers…
Rising interest rates have minimal direct operational impact given negligible debt (0.04 D/E ratio) and no significant refinancing risk.
Watch on earnings: ARISTADA total prescriptions (TRx) and new-to-brand (NBRx) trends from IQVIA prescription data, LYBALVI market share penetration in schizophrenia and bipolar disorder segments, Quarterly royalty revenue from INVEGA franchise as indicator of biosimilar competitive pressure.
One Sentence Summary:
Alkermes: the story is balanced — aristada franchise volume trends and market share versus competing lais (invega sustenna, abilify maintena).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.